Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC lands $16 million judgment against supplement firms

This article was originally published in The Tan Sheet

Executive Summary

The U.S. District Court for the Northern District of Georgia has issued a final monetary judgment and permanent prohibitions against the marketers of dietary supplement products Thermalean and Lipodrene for weight loss and Spontane-ES for erectile dysfunction. Defendants National Urological Group, Hi-Tech Pharmaceuticals and several others are found liable for $15.8 million in deceptive sales based on claims that their products caused 19 percent loss in total body weight and were clinically proven to treat 90 percent of men with ED, the Federal Trade Commission says Jan. 15. The marketers also are barred from making such claims in the absence of scientific evidence. The court granted FTC's motion for summary judgment in June, after the defendants unsuccessfully argued that the "non-actionable puffery" in their ads granted them protection under the FTC Act (1"The Tan Sheet" June 16, 2008, p. 8)

You may also be interested in...

Ruling Against Hi-Tech Pharmaceuticals Spotlights FTC Strategies

A recent court ruling emphasizes Federal Trade Commission strategies to prevent companies from repeatedly making false claims, stretching substantiation data, using deceptive endorsements and creating shell businesses

Sanofi Alliance Is Big Boost For Company Behind Type 1 Diabetes Prevention Drug

Sanofi has deprioritized its presence in type 1 diabetes in recent years but could help turn teplizumab into a game-changer blockbuster product.

Biogen’s RoActemra Biosimilar Begins EU Approvals Process

The European Medicines Agency has accepted Biogen’s marketing authorization submission for its BIIB800, developed by Chinese firm Bio-Thera.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts